Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Richard Pratley MD
Richard E. Pratley MD Associate Editor
Kathleen Dungan MD, MPH
Kathleen M. Dungan MD, MPH Advisory Board
Deborah Wexler MD, MSc
Deborah J. Wexler MD, MSc Associate Editor
See All Experts
featured
Published in Diabetes

Expert Opinion / Commentary · October 01, 2015

Cardiovascular Outcomes and Type 2 Diabetes: EMPA-REG OUTCOME

Silvio Inzucchi MD

 

 Save  Recommend
 Share

Additional Info

  1. Zinman B, Wanner C, Lachin JM, et al for the EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes [published online September 17, 2015]. N Engl J Med. DOI: 10.1056/NEJMoa1504720.

  2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med. 1993;329(14):977-986.

  3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352(9131):837-853.

  4. Dormandy JA, Charbonnel B, Eckland DJ, et al for the PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366(9493):1279-1289.

  5. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med. 2008; 358(24):2545-2559.

  6. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370(9590): 829-840.

  7. Duckworth W, Abraira C, Moritz T, et al for the VADT Investigators. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. N Engl J Med. 2009. 360(2):129-139.
  8. Green JB, Bethel MA, Armstrong PW et al for the TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015; 373(3):232-242.

  9. Pfeffer M, et al. The Evaluation of Lixisenatide in Acute Coronary Syndrome – The Results of ELIXA. Paper presented at: American Diabetes Association 75th Scientific Sessions 2015. June 5-9, 2015; Boston, MA.

  10. White WB, Cannon CP, Heller SR, et al for the EXAMINE Investigators. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Med. 2013; 369(14):1327-1335.
  11. Scirica BM, Bhatt DL, Braunwald E, et al for the SAVOR-TIMI 53 Steering Committee and Investigators Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med 2013; 369(14):1317-1326.

Disclosure statements are available on the authors' profiles:

Silvio Inzucchi MD

Further Reading

Most Read This Week

Recently Updated